Ananthasubramani Rajagopal

Prof. Ananthasubramani Rajagopal


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
ASANITA SAXENA
ANITA SAXENA
SSSanjay Srinivasa
Sanjay Srinivasa
IVIlangovan Veerappan
Ilangovan Veerappan
CJChakko Jacob
Chakko Jacob
AMAmol Mahaldar
Amol Mahaldar
ARAnanthasubramani Rajagopal
Ananthasubramani Rajagopal
Design, participants, setting, and measurements: Predialysis adult participants with chronic kidney disease (CKD) and mean estimated glomerular filtration rate (eGFR) 20 µg/mL) was 53% for the placebo group and 32% for the enzobiotic group. The corresponding levels for IS risk (threshold >20,000 ng/mL) were 35% and 24% for the placebo and enzobiotic groups, respectively. In the placebo group, eGFR decreased by 7% (Day 90) but remained stable (1.00) in the enzobiotic group. QoL as assessed by the adversity ratio decreased significantly (p = 0.00), highlighting an improvement in the enzobiotic group compared to the placebo group. The predictive equations were as follows: PCS (Day 0 = −5.97 + 0.0453 PC + 2.987 UA − 1.310 Creat; IS (Day 0) = 756 + 1143 Creat + 436.0 Creat2. Conclusion: Enzobiotics significantly reduced the PCS and IS, as well as improved the QoL.